A Case of Transverse Myelitis Following Treatment with Atezolizumab for Advanced Hepatocellular Carcinoma
- Author:
Kyung Han KIM
1
;
Yang-Hyun BAEK
;
Yeo Wool KANG
;
Byeol-A YOON
;
Sang Yi MOON
Author Information
- Publication Type:CASE REPORT
- From:The Korean Journal of Gastroenterology 2023;82(1):35-39
- CountryRepublic of Korea
- Language:English
- Abstract: The results of the IMbrave150 study have led to widespread use of the combination therapy of atezolizumab and bevacizumab as a first-line treatment for unresectable or metastatic hepatocellular carcinoma (HCC). Compared to traditional cytotoxic chemotherapy agents, immune checkpoint inhibitors show a spectrum of side effects ranging from mild side effects such as skin rash to potentially severe systemic effects such as myocarditis. We present a case of transverse myelitis diagnosed during the treatment of HCC with atezolizumab and bevacizumab combination therapy.
